UNSPSC 51111748: Ladirubicin

This classification denotes an anthracycline antibiotic with the molecular formula C29H31NO11S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U395ERO49H. The term LADIRUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45. ). Most nations schedule ladirubicin under HS 29419000 and SITC 54139. As of Q4 2014, LADIRUBICIN remains the US FDA Preferred Term for this commodity. Ladirubicin bears US NLM identifiers UMLS ID C2827222 and NCI Concept Code C83861.

SMILES: CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N6CC6)OS(=O)(=O)C.

UNSPSC 51111748 Ladirubicin, a Commodity code, shows minimal recent activity aligned with its nominal scope — the code's name references a specific chemotherapy agent, but state and local solicitations posted under it do not procure ladirubicin itself. Instead, recent opportunities tagged to this code reflect broader pharmaceutical and medical supply purchasing by state agencies, health departments, and municipal fire rescue divisions. The kinds of work actually appearing in state and local procurement under this code include naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products supplied through authorized wholesalers, medical and first aid supplies for emergency responders, and pharmacy benefit program innovation consulting. Issuing bodies span state health agencies (Texas Health and Human Services Commission), cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon), county health departments (Seminole County, Florida), and municipal fire rescue divisions (City of Tampa Fire Department).

Recent solicitations show activity concentrated in Florida, Minnesota, Texas, and the broader cooperative purchasing footprint of MMCAP. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building (response due July 26, 2023). The Minnesota Multistate Cooperative Purchasing Alliance posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026 and awards effective July 1, 2026; the contract term is two years for new vendors with optional extensions. The City of Tampa issued IFB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for its Fire Department Rescue Division, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount and estimated contract value of $700,000, with response due March 13, 2026. Texas HHS issued RFI HHS0017013 in April 2026 to explore vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, with responses due April 3, 2026.